Correlation Between Eupraxia Pharmaceuticals and CERo Therapeutics

Can any of the company-specific risk be diversified away by investing in both Eupraxia Pharmaceuticals and CERo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eupraxia Pharmaceuticals and CERo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eupraxia Pharmaceuticals Common and CERo Therapeutics Holdings, you can compare the effects of market volatilities on Eupraxia Pharmaceuticals and CERo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eupraxia Pharmaceuticals with a short position of CERo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eupraxia Pharmaceuticals and CERo Therapeutics.

Diversification Opportunities for Eupraxia Pharmaceuticals and CERo Therapeutics

0.7

Correlation Coefficient

Eupraxia Pharmaceuticals  CERo Therapeutics

Poor diversification

The 3 months correlation between Eupraxia and CERo is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Eupraxia Pharmaceuticals Commo and CERo Therapeutics Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CERo Therapeutics and Eupraxia Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eupraxia Pharmaceuticals Common are associated (or correlated) with CERo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CERo Therapeutics has no effect on the direction of Eupraxia Pharmaceuticals i.e., Eupraxia Pharmaceuticals and CERo Therapeutics go up and down completely randomly.

Pair Corralation between Eupraxia Pharmaceuticals and CERo Therapeutics

Given the investment horizon of 90 days Eupraxia Pharmaceuticals is expected to generate 25.38 times less return on investment than CERo Therapeutics. But when comparing it to its historical volatility, Eupraxia Pharmaceuticals Common is 6.86 times less risky than CERo Therapeutics. It trades about 0.02 of its potential returns per unit of risk. CERo Therapeutics Holdings is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  7.00  in CERo Therapeutics Holdings on September 24, 2024 and sell it today you would lose (6.10) from holding CERo Therapeutics Holdings or give up 87.14% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	90.11%
Values	Daily Returns

Eupraxia Pharmaceuticals Commo  vs.  CERo Therapeutics Holdings

Eupraxia Pharmaceuticals

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

CERo Therapeutics

Risk-Adjusted Performance

11 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in CERo Therapeutics Holdings are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, CERo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Eupraxia Pharmaceuticals and CERo Therapeutics

The main advantage of trading using opposite Eupraxia Pharmaceuticals and CERo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eupraxia Pharmaceuticals position performs unexpectedly, CERo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will offset losses from the drop in CERo Therapeutics' long position.

The idea behind Eupraxia Pharmaceuticals Common and CERo Therapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.